PMID: 16518133Mar 7, 2006Paper

Somatic augmentation strategies in clozapine resistance--what facts?

Clinical Neuropharmacology
Constantin TranulisDavid Gourion

Abstract

Polypharmacy without evidence-based support is sometimes needed for patients treated with 40% to 70% clozapine who are clozapine nonresponders. Several somatic augmentation strategies are proposed in the scientific literature, with different levels of evidence for safety and efficacy. The purpose of the present study is to review the available literature on the efficacy and safety of clozapine augmentation with somatic agents other than antipsychotics. The following classes of agents are considered: (1) mood stabilizers, (2) antidepressants, (3) electroconvulsive therapy and repetitive transcranial magnetic stimulation, (4) glutamatergic agents, (5)fatty acids supplements, and (6) benzodiazepines. Case controls and small-size clinical trials largely dominate the literature, limiting the power to draw conclusions concerning safety issues and the meaning of negative studies. Moreover, variable definitions of clozapine resistance, heterogeneous outcome measures, and short duration of treatment trials are additional limitations. Generally, adjunctive strategies for clozapine-resistant patients remain based on scarce evidence of efficacy and significant safety concerns. Low-frequency repetitive transcranial magnetic stimulation, fat...Continue Reading

References

Jan 26, 1978·The New England Journal of Medicine·G RothsteinJ W Athens
Aug 15, 1992·Biological Psychiatry·H Rittmannsberger, F Leblhuber
Mar 14, 1991·The New England Journal of Medicine·R J Baldessarini, F R Frankenburg
Aug 6, 1991·Lancet·S L GersonH Meltzer
Jan 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·R Littlewood
Jan 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·S J Masiar, C A Johns
Jan 1, 1989·Psychopharmacology·R GrohmannL G Schmidt
Apr 1, 1995·The American Journal of Psychiatry· Adityanjee
Jan 15, 1995·Biological Psychiatry·W H Wilson
Jan 1, 1995·Pharmacopsychiatry·J TiihonenP Hakola
Apr 1, 1995·Journal of Clinical Psychopharmacology·L E Costello, T Suppes
Dec 1, 1994·Journal of Clinical Psychopharmacology·G GarciaP G Dorson
May 1, 1994·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·P Toth, F R Frankenburg
Jan 1, 1993·International Clinical Psychopharmacology·A ValevskiA Weizman
Sep 1, 1995·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·C W JacksonT D Brewerton
Feb 1, 1996·Acta Psychiatrica Scandinavica·G BushA Francis
Jan 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·B HellwigJ Walden
Aug 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·Y BlochI Mor
Dec 1, 1996·The American Journal of Psychiatry·R W BuchananA Breier
Dec 1, 1996·The American Journal of Psychiatry·D C GoffJ T Coyle
Aug 1, 1997·The British Journal of Psychiatry : the Journal of Mental Science·D Taylor
Feb 4, 1998·The Journal of Clinical Psychiatry·I FaisalR Cancro
Feb 24, 1998·Journal of Clinical Psychopharmacology·P H Silverstone
Oct 30, 1998·The Psychiatric Quarterly·Z A Sharif
Jan 19, 1999·Archives of General Psychiatry·N B FarberJ W Olney
Jan 19, 1999·Archives of General Psychiatry·U Heresco-LevyM Lichtenstein
Jan 19, 1999·The American Journal of Psychiatry·S G PotkinB Gulasekaram
Feb 3, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·I AnghelescuH Wetzel
Feb 13, 1999·International Clinical Psychopharmacology·D TaylorR Murray
Apr 29, 1999·International Clinical Psychopharmacology·D V James, N S Gray
Jun 23, 1999·Progress in Neuro-psychopharmacology & Biological Psychiatry·H C KalesR Tandon
Feb 2, 2000·Psychiatric Services : a Journal of the American Psychiatric Association·S A ChongK Z Bezchlibnyk-Butler
Feb 22, 2000·Clinical Neuropharmacology·M KupchikM Kotler
Mar 4, 2000·The American Journal of Psychiatry·S I UsiskinJ L Rapoport

❮ Previous
Next ❯

Citations

May 4, 2011·Acta Psychiatrica Scandinavica·J NielsenD Taylor
Feb 24, 2015·Acta Neuropsychiatrica·Sandeep GroverNatasha Kate
Apr 1, 2011·Therapeutic Advances in Psychopharmacology·Seema VarmaDavid Taylor
Aug 11, 2007·International Clinical Psychopharmacology·A Carlo AltamuraHerbert Y Meltzer
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Aug 21, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Mayra Alejandra Santillán-UrquizaJaime Tortoriello
Nov 25, 2016·The Cochrane Database of Systematic Reviews·Yijun WangStefan Leucht

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here